News | March 31, 2023
Evonik starts construction of US$220 million lipid innovation center in Lafayette
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The inspection concluded with no observations
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
None of the observations are related to data integrity and management believes that they are addressable
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Subscribe To Our Newsletter & Stay Updated
